Cheplapharm Arzneimittel Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 750

Employees

  • Latest Deal Type
  • General Corporate Purpose

  • Financing Rounds
  • 14

  • Investments
  • 24

Cheplapharm Arzneimittel General Information

Description

Cheplapharm AG is a family-run pharmaceutical German company. The firm offers a portfolio covering a range of therapeutic areas and indications including cardiology, gastroenterology, gynaecology, haematology, immunology, etc. It also produces medicines that help with sleep disorders, mental illness and infectious diseases. Key turnover is generated in Europe, countries in Asia, the Americas and the rest of the world.

Contact Information

Website
www.cheplapharm.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Ziegelhof 24
  • 17489 Greifswald
  • Germany
+49 03834 00000
Primary Industry
Pharmaceuticals
Former Stock Listing
PCPH
Corporate Office
  • Ziegelhof 24
  • 17489 Greifswald
  • Germany
+49 03834 00000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cheplapharm Arzneimittel Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cheplapharm Arzneimittel‘s full profile, request access.

Request a free trial

Cheplapharm Arzneimittel Patents

  • 108

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 57

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Cheplapharm Arzneimittel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2007332640-B2 Powder formulation for valganciclovir Active 13-Dec-2006 000000000
AU-2007332640-A1 Powder formulation for valganciclovir Active 13-Dec-2006 000000000
CA-2671470-C Powder formulation for valganciclovir Active 13-Dec-2006 0000000000
US-20190117775-A1 Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride Active 13-Dec-2006 000000000
US-20130150382-A1 Novel pharmaceutical dosage forms comprising valganciclovir hydrochloride Active 13-Dec-2006 A61K47/12
To view Cheplapharm Arzneimittel’s complete patent history, request access »

Cheplapharm Arzneimittel Executive Team (8)

Name Title Board Seat
Edeltraud Lafer Co-Chief Executive Officer
Sebastian Braun Co-Chief Executive Officer
Kia Parssanedjad Chief Financial Officer
Klaus Köhl Chief Operating Officer & Managing Director
Bianca Juha MD Chief Scientific Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Cheplapharm Arzneimittel Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cheplapharm Arzneimittel Investments & Acquisitions (24)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Roche (Global Rights to Roaccutan) 18-Jan-2024 000000000 Buildings and Property 000000000
Eli Lilly (Marketing Rights) 25-Apr-2023 000000000 00.00 Buildings and Property
Sanofi (10 established products) 31-Mar-2022 000000000 Pharmaceuticals
Bristol Myers Squibb (Portfolio of Three Chemotherapeutical Medicinal Products in New York) 01-Mar-2022 000000000 Drug Discovery 000000000
Astellas (Product Rights For Flemoxin, Unidox, De Nol, Suprax and Orbenine in Europe and Russia) 16-Jun-2021 Corporate Asset Purchase 00000 Buildings and Property
You’re viewing 5 of 24 investments and acquisitions. Get the full list »

Cheplapharm Arzneimittel FAQs

  • When was Cheplapharm Arzneimittel founded?

    Cheplapharm Arzneimittel was founded in 1998.

  • Who is the founder of Cheplapharm Arzneimittel?

    Kurt Teubner is the founder of Cheplapharm Arzneimittel.

  • Who is the CEO of Cheplapharm Arzneimittel?

    Edeltraud Lafer and Sebastian Braun are the CEOs of Cheplapharm Arzneimittel.

  • Where is Cheplapharm Arzneimittel headquartered?

    Cheplapharm Arzneimittel is headquartered in Greifswald, Germany.

  • What is the size of Cheplapharm Arzneimittel?

    Cheplapharm Arzneimittel has 750 total employees.

  • What industry is Cheplapharm Arzneimittel in?

    Cheplapharm Arzneimittel’s primary industry is Pharmaceuticals.

  • Is Cheplapharm Arzneimittel a private or public company?

    Cheplapharm Arzneimittel is a Private company.

  • What is Cheplapharm Arzneimittel’s current revenue?

    The current revenue for Cheplapharm Arzneimittel is 000000.

  • How much funding has Cheplapharm Arzneimittel raised over time?

    Cheplapharm Arzneimittel has raised $4.15B.

  • When was Cheplapharm Arzneimittel acquired?

    Cheplapharm Arzneimittel was acquired on 10-Aug-2023.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »